Eli Lilly announced a $3 billion investment to build a new manufacturing facility in Katwijk, Netherlands, within the Leiden Bio Science Park. The plant will produce its oral GLP‑1 receptor agonist orforglipron and other oral medicines across cardiometabolic, oncology, immunology, and neuroscience portfolios.
The facility is part of Lilly’s strategy to expand its global manufacturing footprint and strengthen its supply chain. By localizing production in Europe, the company aims to reduce supply‑chain bottlenecks, accelerate regulatory submissions, and meet the projected demand for orforglipron, which is expected to launch globally in 2026.
The investment complements Lilly’s $50 billion U.S. manufacturing build‑out since 2020, which includes four new sites and a Puerto Rico expansion. The company’s Q3 2025 revenue of $17.6 billion, a 54% year‑over‑year increase, underpins the capital allocation and supports the company’s raised full‑year 2025 revenue forecast of $63‑$63.5 billion.
Lilly’s orforglipron is positioned to capture a share of the rapidly growing obesity market. GlobalData projects sales of $11 billion by 2031, and Lilly expects to submit the drug to global regulatory agencies for obesity by the end of 2025. The new facility will enable the company to scale production to meet this demand and maintain its competitive position against rivals such as Novo Nordisk, which is preparing to launch oral semaglutide in late 2025.
CEO David A. Ricks said the new plant will “strengthen Lilly’s manufacturing capacity in Europe and support the launch of orforglipron and other oral medicines.” The investment reflects Lilly’s commitment to expanding its oral GLP‑1 portfolio and reinforcing its position in the cardiometabolic market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.